Department of Otolaryngology/Head-Neck Surgery, VU University Medical Center, Amsterdam, The Netherlands.
Oral Oncol. 2010 Jul;46(7):485-91. doi: 10.1016/j.oraloncology.2010.01.019. Epub 2010 Feb 26.
The relatively modest survival of patients surgically treated for advanced HNSCC can partly be explained by the development of local relapse. It is important that surgeons are able to predict which patients are at high risk to develop local relapse, since clinical management can be tailored. Local relapse after resection of a primary HNSCC is easily explained, when tumour is detected in the surgical margins and thus residual tumour is likely to remain in the patient, but the pathobiology is more complex in cases where the margins are histologically tumour-free. Molecular studies indicate that there are two different mechanisms responsible in these cases. First, small clusters of residual tumour cells that are undetectable on routine histopathological examination (known as minimal residual cancer: MRC) proliferate and this forms the basis of recurring cancer. A second cause of relapse is a remaining field of preneoplastic cells that is struck by additional genetic hits leading to invasive cancer. It is likely that within this field, that can be over 7cm in diameter, the primary carcinoma has also emerged. Despite careful histopathological examination of the surgical margins of the primary carcinoma, it is at present not reliably possible to predict which patient will develop local relapse. Herein we focus on new developments regarding the analysis of margins, causes of local relapse, and how novel molecular techniques can be of help in a more accurate risk assessment. Critical analysis of the studies that have been published thus far shows that there is a list of promising markers, based on protein expression (immuno-histochemistry) and nucleic acid analysis. Further studies should be focused on validation and assessment of the clinical utility of these markers. Margin analysis should reveal whether one is dealing with residual cancer cells that might be treated by post-operative radiotherapy or with preneoplastic fields that remained behind. For this latter entity, there is no intervention available at present, except for a more intensive surveillance.
接受手术治疗的晚期头颈部鳞癌患者的生存率相对较低,部分原因是局部复发。重要的是,外科医生能够预测哪些患者有发生局部复发的高风险,因为可以根据预测结果调整临床管理策略。原发性头颈部鳞癌切除后发生局部复发很容易解释,当肿瘤在手术切缘处被检测到时,肿瘤可能会残留在患者体内,但在切缘组织学上无肿瘤的情况下,其病理生物学更为复杂。分子研究表明,在这些情况下有两种不同的机制负责。首先,在常规组织病理学检查中无法检测到的少量残留肿瘤细胞(称为微小残留癌:MRC)会增殖,这是复发性癌症的基础。复发的第二个原因是残留的具有潜在癌变的细胞受到额外的遗传打击,导致浸润性癌症。很可能在这个直径超过 7cm 的区域内,原发性癌也已经出现。尽管对原发性癌的手术切缘进行了仔细的组织病理学检查,但目前仍无法可靠地预测哪些患者会发生局部复发。本文重点介绍了关于切缘分析、局部复发原因以及如何利用新的分子技术进行更准确的风险评估的新进展。对迄今为止发表的研究进行批判性分析表明,基于蛋白质表达(免疫组织化学)和核酸分析,有一系列有前途的标记物。进一步的研究应集中在验证和评估这些标记物的临床实用性上。切缘分析应揭示是否处理的是残留的肿瘤细胞,这些细胞可能需要术后放疗,还是处理遗留的具有潜在癌变的组织。对于后者,目前没有干预措施,只能进行更密集的监测。